# A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

> **NCT04504916** · PHASE2 · TERMINATED · sponsor: **VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 102 (actual)

## Conditions studied

- Triple-negative Breast Cancer
- Non-squamous Non-small-cell Lung Cancer
- NSCLC
- Estrogen-receptor-positive Breast Cancer
- Progesterone-receptor-positive Breast Cancer
- Estrogen-receptor-negative Breast Cancer
- ER-negative Breast Cancer
- Progesterone-receptor Negative Breast Cancer
- PR-negative Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer
- PR-positive Breast Cancer
- Platinum-resistant Ovarian Cancer
- Gastric Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** Zilovertamab vedotin

## Key facts

- **NCT ID:** NCT04504916
- **Lead sponsor:** VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-07
- **Primary completion:** 2023-06-12
- **Final completion:** 2023-06-12
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504916, "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04504916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*